Emerging Drug Discovery Targets; June 28th

Emerging Drug Discovery Targets

from

to view this alert on line please go to http://www.leaddiscovery.co.uk/TherapeuticAdvances%20Archive/June%2028th%20emerging%20targets.htm

**************************************

"Emerging Drug Discovery Targets" provides a regular summary of some of the most exciting breaking information recently featured by the pharmaceutical analysts, . Information includes editorials on recently published journal articles, selected press releases and "intelligence reports". Our target audience includes business development personnel, senior management and researchers within the drug development sector as well as bioscience investors and analysts.

Please feel free to pass this mail onto colleagues that may benefit from registration to Emerging Drug Discovery Targets. To register click here.

**************************************

In this weeks edition:

• Editorial comment on selected journal articles
• Exploiting the peptide uptake transporters PEPT1 and PEPT2 to improve drug absorption and targeting [more]
• The development of a dual 5-LO inhibitor/H1 receptor antagonist for the treatment of asthma [more]
• Sitaxentan as an effective treatment of pulmonary arterial hypertension [more]
• Kv1.3 potassium channel blockade as an approach to insulin resistance [more]
• Drug delivery technology predicted to allow safer and more effective use of steroids in the treatment of rheumatoid arthritis [more]
• Novartis’/Schering’s VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584 as a candidate treatment of rheumatoid arthritis [more]
• PharmaNews Bytes - June 2004
• News from the American Diabetes Association's summer conference: Exenatide; LAF 237A; EXUBERA [more]
• News from the American Society of Clinical Oncology: Statins as chemopreventative agents; changing attitudes to first line treatment of colorectal cancer [more]
• Advances in the treatment of schizophrenia & bipolar disorder [more]
• The development of novel HIV therapeutics [more]
• Today's breaking scientific publications for the drug development community [more]
• Also available for the following therapeutic areas on subscription only
• Oncology
• Cardiovascular disease
• Inflammation, Infectious diseases and Immunology
• CNS disorders
• Metabolic disorders
• Current licensing opportunities [more]
• Selected new PharmaReports:
• Insulin Use in Type 2 Diabetes - From Last Resort to Early Intervention
• Antifungals - More Data, More Prescriptions
• Monoclonal Antibodies in Cancer Therapy: Emerging Products and Markets
• Anxiety Disorders - More Than Just a Comorbidity
• Cancer Genomics: Revolutionizing Treatment and Reshaping Markets through Targeted Therapies
• Gene Therapy - technologies, markets and companies
• HIV - Enter the New Generation Inhibitors
• [more]
• Emerging Drug Discovery Targets archive